In this edition, FDA approves supplemental new drug application for Rexulti, early amyloid PET provides high diagnostic confidence, Leqembi reduced biomarkers of Alzheimer's and more. Read the full coverage here: FDA approves supplemental new drug application for Rexulti to treat Alzheimer's agitation Early amyloid PET provides high diagnostic confidence for adults with cognitive impairment Leqembi reduced biomarkers of Alzheimer's, slowed cognitive decline at 18 months FDA grants 510(k) clearance for self-directed EEG headset Oral Bruton's tyrosine kinase inhibitor reduced brain lesions in phase 2 MS trial References: Altomare D, et al. JAMA Neurol. 2023;doi:10.1001/jamaneurol.2023.0997. Press Release Press Release Press Release Van Dyck CH, et al. A study to confirm safety and efficacy of lecanemab in participants with early Alzheimer's disease (Clarity AD). Presented at: American Academy of Neurology annual meeting; April 22-27, 2023; Boston.

Ver todos los episodios